192 related articles for article (PubMed ID: 37201866)
1. Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: A systematic scoping review and narrative synthesis.
Reynolds G; Sim B; Anderson MA; Spelman T; Teh BW; Slavin MA; Thursky KA
Clin Microbiol Infect; 2023 Oct; 29(10):1280-1288. PubMed ID: 37201866
[TBL] [Abstract][Full Text] [Related]
2. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
7. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
8. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
9. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
10. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.
Pérez-Moreno MA; Ciudad-Gutiérrez P; Jaramillo-Ruiz D; Reguera-Ortega JL; Abdel-Kader Martín L; Flores-Moreno S
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834228
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies.
Saiz LC; Leache L; Gutiérrez-Valencia M; Erviti J; Rojas Reyes MX
Ther Adv Hematol; 2023; 14():20406207231168211. PubMed ID: 37138698
[TBL] [Abstract][Full Text] [Related]
12. Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis.
Reynolds GK; Sim B; Spelman T; Thomas A; Longhitano A; Anderson MA; Thursky K; Slavin M; Teh BW
Crit Rev Oncol Hematol; 2023 Dec; 192():104134. PubMed ID: 37739146
[TBL] [Abstract][Full Text] [Related]
13. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
Haidar G; Garner W; Hill JA
Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
[TBL] [Abstract][Full Text] [Related]
14. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis.
Telli Dizman G; Aguado JM; Fernández-Ruiz M
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1455-1476. PubMed ID: 36148506
[TBL] [Abstract][Full Text] [Related]
15. Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Lalu MM; Kekre N; Montroy J; Ghiasi M; Hay K; McComb S; Weeratna R; Atkins H; Hutton B; Yahya A; Masurekar A; Sobh M; Fergusson DA
Syst Rev; 2023 Jan; 12(1):9. PubMed ID: 36653879
[TBL] [Abstract][Full Text] [Related]
16. Prolonged duration of lymphocyte deficiency, high-grade CRS, and ventilation are linked to fungal breakthrough in patients with hematologic malignancies 60 days after CAR-T infusion: A single center case-control study.
Yang J; Zhang J; Wei J; Wu G; Song J; Liu D; He Y
J Infect Public Health; 2022 Dec; 15(12):1521-1530. PubMed ID: 36434996
[TBL] [Abstract][Full Text] [Related]
17. Reporting infections in clinical trials of patients with haematological malignancies.
Tau N; Shargian-Alon L; Reich S; Paul M; Gafter-Gvili A; Shepshelovich D; Yahav D
Clin Microbiol Infect; 2019 Dec; 25(12):1494-1500. PubMed ID: 31100423
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies.
Zhu F; Wei G; Liu Y; Zhou H; Wu W; Yang L; Huang H; Hu Y
Cell Transplant; 2021; 30():9636897211025503. PubMed ID: 34144648
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review (protocol).
Leache L; Gutiérrez Valencia M; Saiz LC; Erviti J; Rojas Reyes MX
Open Res Eur; 2022; 2():38. PubMed ID: 38827275
[TBL] [Abstract][Full Text] [Related]
20. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
Xiao X; Wang Y; Zou Z; Yang Y; Wang X; Xin X; Tu S; Li Y
Front Immunol; 2022; 13():954235. PubMed ID: 36091028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
